Literature summary for 5.3.99.5 extracted from

Uematsu, T.; Kosuge, K.; Umemura, M.; Nakano, M.; Terakawa, M.; Nakashima, M.
Pharmacokinetic and pharmacodynamic properties of FK070(KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers (1996), J. Pharm. Pharmacol., 48, 380-385.

Search for more literature for 5.3.99.5

Application

Application	Comment	Organism
medicine	the thromboxane A2 synthetase inhibitor/thromboxane A2-receptor antagonist (5Z)-6-[(2S,4R)-4-(4-chlorophenylsulfonylamino)-1-(3-pyridylmethyl)-2-pyrrolidinyl]-5-hexenoic acid hydrochloride may be of clinical relevance for the prevention or treatment of th	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
(5Z)-6-[(2S,4R)-4-(4-Chlorophenylsulphonylamino)-1-(3-pyridylmethyl)-2-pyrrolidinyl]-5-hexenoic acid hydrochloride	thromboxane A2 synthetase inhibitor/thromboxane A2-receptor antagonist	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
Prostaglandin H2	i.e. PGH2	Homo sapiens	thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid	-	?

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)